Skip to main content

Advertisement

Table 4 Statistical analysis for OS and PFS.

From: Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life

Univariate Analysis for Overall Survival (OS) cancer patients with brain metastases
  OS (months) 95% C.I. P value
Radiological response:    
Tumor control (SD, CR, PR) 13.00 12.35 – 13.65 < 0.0001
Brain progression (PD) 5.00 3.83 – 6.17  
Lung Cancer 13.00 12.10 – 13.90 0.9263
All the others 12.00 10.32 – 13.68  
Males 11.00 7.63 – 14.37 0.239
Females 13.00 12.22 – 13.78  
KPS <70 5.00 2.39 – 7.61 0.0006
KPS ≥ 70 13.00 12.37 – 13.63  
No previous chemotherapy 13.00 11.53 – 14.47 0.7568
Previous chemotherapy 12.00 10.86 – 13.14  
No extracranial disease 13.00 13.19 – 14.81 0.0681
Extracranial disease 10.00 7.31 – 14.69  
Age > 65 years 6.00 2.56 – 9.23 0.0050
Age ≤ 65 years 12.00 10.01 – 13.67  
RPA 1 13.00 11.95 – 14.05 0.0025
RPA 2 13.00 12.16 – 13.84  
RPA 3 5.00 2.39 – 7.61  
Univariate Analysis for Progression Free Survival (PFS) cancer patients with brain metastases
  PFS (months) 95% C.I. P value
Radiological response:    
Tumor control (SD, CR, PR) 10.00 8.54 – 11.46 < 0.0001
Brain progression (PD) 4.00 3.63 – 4.37  
Lung Cancer 9.00 7.85 – 10.15 0.3578
All the others 10.00 7.67 – 12,33  
Males 9.00 7.42 – 10.58 0.4815
Females 9.00 6.50 – 11.50  
KPS <70 4.00 3.22 – 4.78 0.0016
KPS ≥ 70 10.00 8.40 – 11.60  
No previous chemotherapy 10.00 8.05 – 11.95 0.7835
Previous chemotherapy 8.00 6.73 – 9.27  
No extracranial disease 11.00 9.54 – 12.45 0.0247
Extracranial disease 8.00 5.80 – 10.20  
Age > 65 years 5.00 4.10 – 6.43 0.02
Age ≤ 65 years 10.00 7.22 – 11.98  
RPA 1 11.00 8.56 – 13.44 0.0027
RPA 2 9.00 7.25 – 10.75  
RPA 3 4.00 3.22 – 4.78